Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC).

Titre officiel

A Phase III Randomized, Open-Label, Multi-Centre, Global Study of MEDI4736 in Combination With Tremelimumab Therapy or MEDI4736 Monotherapy Versus Standard of Care Platinum-Based Chemotherapy in First Line Treatment of Patients With Advanced or Metastatic Non Small-Cell Lung Cancer (NSCLC) (MYSTIC)

Sommaire:

Une étude multicentrique globale de phase III à répartition aléatoire, en mode ouvert visant à évaluer l'efficacité et l'innocuité de l'association médicamenteuse MEDI4736-tremelimumab et de MEDI4736 en monothérapie comparativement à une chimiothérapie traditionnelle de première intention à base de platine chez des patients atteints d'un CPNPC localement avancé ou métastatique comprenant la mutation du gène du récepteur du facteur de croissance épidermique (R-EGF) et le gène de fusion du lymphome anaplasique (ALK)

Description de l'essai

Primary Outcome:

  • Overall Survival (OS); PD-L1 (TC >=25%) Analysis Set Population, Durvalumab Monotherapy Vs SoC Chemotherapy and Durvalumab + Tremelimumab Vs SoC Chemotherapy
  • Progression-Free Survival (PFS); PD-L1 (TC >=25%) Analysis Set Population, Durvalumab + Tremelimumab Vs SoC Chemotherapy
Secondary Outcome:
  • OS; PD-L1 (TC >=25%) Analysis Set Population, Durvalumab + Tremelimumab Vs Durvalumab Monotherapy
  • OS; PD-L1 (TC >=1%) Analysis Set Population
  • OS; FAS Population
  • PFS; PD-L1 (TC >=25%) Analysis Set Population, Durvalumab Monotherapy Vs SoC Chemotherapy and Durvalumab + Tremelimumab Vs Durvalumab Monotherapy
  • PFS; PD-L1 (TC >=1%) Analysis Set Population
  • PFS; FAS Population
  • Objective Response Rate (ORR); PD-L1 (TC >=25%) Analysis Set Population
  • ORR; PD-L1 (TC >=1%) Analysis Set Population
  • ORR; FAS Population
  • Duration of Response (DoR); PD-L1 (TC >=25%) Analysis Set Population
  • DoR; PD-L1 (TC >=1%) Analysis Set Population
  • DoR; FAS Population
  • Percentage of Participants Alive and Progression Free at 12 Months (APF12); PD-L1 (TC >=25%) Analysis Set Population
  • Percentage of Participants APF12; PD-L1 (TC >=1%) Analysis Set Population
  • Percentage of Participants APF12; FAS Population
  • Time From Randomization to Second Progression (PFS2); PD-L1 (TC >=25%) Analysis Set Population
  • PFS2; PD-L1 (TC >=1%) Analysis Set Population
  • PFS2; FAS Population
  • Change From Baseline in Disease-Related Symptoms as Assessed by European Organisation for Research and Treatment of Cancer Quality of Life Questionnaires (EORTC QLQ) at 12 Months
  • Serum Concentrations of Durvalumab
  • Serum Concentrations of Tremelimumab
  • Maximum Serum Concentration at Steady State (Cmax_ss) of Durvalumab
  • Cmax_ss of Tremelimumab
  • Trough Serum Concentration at Steady State (Ctrough_ss) of Durvalumab
  • Ctrough_ss of Tremelimumab
  • Number of Participants With Anti-Drug Antibody (ADA) Response to Durvalumab
  • Number of Participants With ADA Response to Tremelimumab
Patients will be randomized in a 1:1:1 ratio to receive treatment with MEDI4736 + tremelimumab combination therapy, MEDI4736 monotherapy, or Standard of Care (SoC) therapy.

Voir cet essai sur ClinicalTrials.gov

Intéressé(e) par cet essai?

Imprimez cette page et apportez-la chez votre médecin pour discuter de votre admissibilité à cet essai et des options de traitement. Seul votre médecin peut vous recommander pour un essai clinique.

Ressources

Société canadienne du cancer

Ces ressources sont fournies en partenariat avec Société canadienne du cancer